Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
| Autor: | Lakshmi Sukumaran, Cindy M. Weinbaum, Julianne Gee, Lauri E. Markowitz |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Vaccine safety
medicine.medical_specialty Immunology MEDLINE Reviews Syncope 03 medical and health sciences 0302 clinical medicine Human Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18 030225 pediatrics Immunology and Allergy Medicine Adverse Drug Reaction Reporting Systems Humans 030212 general & internal medicine Human papillomavirus Adverse effect Safety monitoring Pharmacology business.industry United States Vaccination Family medicine Epidemiological Monitoring business |
| Zdroj: | Human Vaccines & Immunotherapeutics |
| ISSN: | 2164-554X |
| Popis: | Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination, both pre-licensure and post-licensure 4vHPV safety data have been reassuring with no confirmed safety signals identified. Nine-valent HPV vaccine (9vHPV) was licensed in 2014. This review includes post-licensure 4vHPV safety findings published to date that have informed the US vaccination program; these data will inform US safety monitoring and evaluation for 9vHPV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|